Skip to content
2000
Volume 24, Issue 1
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Metformin is a widely used drug in patients with type 2 diabetes mellitus. Metformin inhibits hepatic gluconeogenesis and increases glucose utilization in peripheral tissues. In recent years, several studies have shown that metformin is a potential therapeutic agent against cancer, alone or combined with other anticancer treatments. Metformin mainly activates the AMPK complex and regulates intracellular energy status, inhibiting the mitochondrial respiratory chain complex I and reducing the production of reactive oxygen species. Other anticancer targets of metformin are specific transcription factors inhibiting cell proliferation, promoting apoptosis and reducing drug resistance. In addition, metformin modulates tumor cells' response to anticancer treatments, favoring the activity of T cells. In diabetic patients, metformin reduces the occurrence of cancer and improves the prognosis and efficacy of anticancer treatments. In this review, we provided a comprehensive perspective of metformin as an anticancer drug.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450124666221104094918
2023-01-01
2024-11-12
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450124666221104094918
Loading

  • Article Type:
    Review Article
Keyword(s): AMPK complex; anticancer; ICIs; Metformin; ROS; Sps
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test